142 related articles for article (PubMed ID: 19347334)
21. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
Shin D; Shin KH; Lee S; Lim KS; Cho JY; Jang IJ; Shin SG; Yu KS
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):722-8. PubMed ID: 22853865
[TBL] [Abstract][Full Text] [Related]
22. Lurasidone drug-drug interaction studies: a comprehensive review.
Chiu YY; Ereshefsky L; Preskorn SH; Poola N; Loebel A
Drug Metabol Drug Interact; 2014; 29(3):191-202. PubMed ID: 24825095
[TBL] [Abstract][Full Text] [Related]
23. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
[TBL] [Abstract][Full Text] [Related]
25. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.
Böhmer GM; Drollmann A; Gleiter CH; Nave R
Clin Pharmacokinet; 2008; 47(5):343-9. PubMed ID: 18399715
[TBL] [Abstract][Full Text] [Related]
26. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine.
Malhotra B; Gandelman K; Sachse R; Wood N
J Clin Pharmacol; 2009 Apr; 49(4):477-82. PubMed ID: 19246724
[TBL] [Abstract][Full Text] [Related]
29. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
[TBL] [Abstract][Full Text] [Related]
30. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U; Miller WH; Hotte S; Evans TR; Kollmansberger C; Adamson D; Nielsen DL; Spicer J; Chen E; Meyer T; Brown K; Rafi R; Sawyer MB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):543-9. PubMed ID: 23196640
[TBL] [Abstract][Full Text] [Related]
31. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
[TBL] [Abstract][Full Text] [Related]
32. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
Boinpally R; Gad N; Gupta S; Periclou A
Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
[TBL] [Abstract][Full Text] [Related]
33. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
[TBL] [Abstract][Full Text] [Related]
34. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
[TBL] [Abstract][Full Text] [Related]
35. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine.
de Mey C; Mateva L; Krastev Z; Sachse R; Wood N; Malhotra B
J Clin Pharmacol; 2011 Mar; 51(3):397-405. PubMed ID: 20371737
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
[TBL] [Abstract][Full Text] [Related]
37. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
Brynne N; Böttiger Y; Hallén B; Bertilsson L
Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648
[TBL] [Abstract][Full Text] [Related]
38. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
39. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
Michel MC
Expert Opin Pharmacother; 2008 Jul; 9(10):1787-96. PubMed ID: 18570610
[TBL] [Abstract][Full Text] [Related]
40. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]